Trial Profile
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients With Malignant Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 01 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Feb 2013 Planned End Date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 14 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2012 as reported by ClinicalTrials.gov.